Eli Lilly's Foundayo Weight-Loss Pill Sees Sluggish Start in Second Week

15 articles · Updated · Bloomberg · Apr 24

Foundayo recorded 3,707 prescriptions in its second week, far behind Novo Nordisk’s oral Wegovy, which saw 18,410 prescriptions in the same period.
The slower uptake highlights the challenge Eli Lilly faces as it competes in the growing obesity drug market.
Novo Nordisk’s strong early sales underscore its lead, intensifying the rivalry between the two pharmaceutical giants in weight-loss treatments.

Can flexible dosing overcome a rival's head start in the weight-loss pill race?

How will the crackdown on compounded drugs reshape the battle for the obesity market?

What if the early prescription data for Lilly's new pill is misleading?

With next-gen drugs on the horizon, are today's new pills already obsolete?

Will new Medicare models make weight-loss pills affordable for more Americans in 2027?